Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
Ontology highlight
ABSTRACT: This is a two arm, 2-center, Phase II, study of 5-FU, irinotecan, bevacizumab (FOLFIRI-beva) and hydroxychloroquine (HCQ) in patients with previously untreated metastatic colorectal cancer (mCRC).
Up to 155 patients will be screened for DTP-signature and up to 31 evaluable patients who are determined to be DTP-signature high will be treated with FOLFIRI-beva and HCQ.
Patients will continue to receive treatments until evidence of disease progression, intolerable side effects, withdrawal of consent or death.
DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 58886 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA